Supplementary Methods. Treatment â endocrine therapy. Treatment â chemotherapy. Treatment â chemotherapy followed by endocrine therapy. Table S1. Frequency of endocrine therapy. Table S2. Frequency of chemotherapy agent. Table S3. Frequency of chemotherapy followed by endocrine therapy. (DOCX 30 kb
Patient characteristics of the 6,248 patients shown by trial. Table S2. National Cancer Institute Co...
Figure S1. Age-adjusted overall survival by breast cancer molecular subtypesa. a Luminal A - ER posi...
Figure S2. Anti-proliferative effect of RAD001 in combination with endocrine agents (a) 4-OHT and (b...
Abstract Background In this study, we observe the patterns initial palliative treatment for premenop...
Survival benefit from adjuvant endocrine therapy in 55 out of the 64 ERâ/PgR+/HER2â cases. (DOC ...
Table S1. Chemotherapy receipt by age group, with age separated into three tiers using 35 and 50 yea...
Figure S1. No difference in overall survival by use of chemotherapy for patients diagnosed betwee...
Common quality indicators valid across time intervals. Quality indicators of guideline adherence and...
Quality indicators valid in each time-interval. Quality indicators of guideline adherence and guidel...
Table S1. Hazard ratio (HR) and 95% confidence intervals (95% CIs) for discontinuation of adjuvant h...
Supplemental results containing: 1) a table comparing trial participants for whom AR expression was ...
Table S1. Characteristics of patients diagnosed with ER/PR-positive first breast cancer enrolled in ...
Figure S2. DFS and OS analysis of > 8 years of endocrine therapy versus < 8 years of endocrine thera...
Figure S1 Overall survival curves by PAM50 classification (for A-F) all patients from METABRIC cohor...
Table S1. Multivariate-adjusteda hazard ratios (HRs) and 95% confidence intervals for breast cancer ...
Patient characteristics of the 6,248 patients shown by trial. Table S2. National Cancer Institute Co...
Figure S1. Age-adjusted overall survival by breast cancer molecular subtypesa. a Luminal A - ER posi...
Figure S2. Anti-proliferative effect of RAD001 in combination with endocrine agents (a) 4-OHT and (b...
Abstract Background In this study, we observe the patterns initial palliative treatment for premenop...
Survival benefit from adjuvant endocrine therapy in 55 out of the 64 ERâ/PgR+/HER2â cases. (DOC ...
Table S1. Chemotherapy receipt by age group, with age separated into three tiers using 35 and 50 yea...
Figure S1. No difference in overall survival by use of chemotherapy for patients diagnosed betwee...
Common quality indicators valid across time intervals. Quality indicators of guideline adherence and...
Quality indicators valid in each time-interval. Quality indicators of guideline adherence and guidel...
Table S1. Hazard ratio (HR) and 95% confidence intervals (95% CIs) for discontinuation of adjuvant h...
Supplemental results containing: 1) a table comparing trial participants for whom AR expression was ...
Table S1. Characteristics of patients diagnosed with ER/PR-positive first breast cancer enrolled in ...
Figure S2. DFS and OS analysis of > 8 years of endocrine therapy versus < 8 years of endocrine thera...
Figure S1 Overall survival curves by PAM50 classification (for A-F) all patients from METABRIC cohor...
Table S1. Multivariate-adjusteda hazard ratios (HRs) and 95% confidence intervals for breast cancer ...
Patient characteristics of the 6,248 patients shown by trial. Table S2. National Cancer Institute Co...
Figure S1. Age-adjusted overall survival by breast cancer molecular subtypesa. a Luminal A - ER posi...
Figure S2. Anti-proliferative effect of RAD001 in combination with endocrine agents (a) 4-OHT and (b...